Time to response in patients with ALK plus NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies

被引：0
|
作者：
Gandhi, L. [1 ]
Gadgeel, S. [2 ]
Shaw, A. [3 ]
Barlesi, F. [4 ]
Crino, L. [5 ]
Yang, J. C-H. [6 ,7 ]
Dingemans, A-M. C. [8 ]
Kim, D-W. [9 ]
de Marinis, F. [10 ]
Schulz, M. [11 ]
Liu, S. [11 ]
Fish, S. [11 ]
Kotb, A. [12 ]
Ou, S-H. I. [13 ]
机构：
[1] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[2] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[4] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[5] Santa Maria della Misericordia Hosp, Med Oncol, Perugia, Italy
[6] Natl Taiwan Univ Hosp, Grad Inst Oncol, Taipei, Taiwan
[7] Natl Taiwan Univ Hosp, Canc Res Ctr, Taipei, Taiwan
[8] MUMC, Pulmonol, Maastricht, Netherlands
[9] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea
[10] European Inst Oncol, Thorac Inst Oncol, Milan, Italy
[11] Genentech Inc, US Med Affairs, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA
[12] F Hoffmann La Roche Ltd, Med Affairs, Basel, Switzerland
[13] Univ Calif Irvine, Med Oncol, Orange, CA 92668 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1209PD
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC)
    Jie, He
    Han, Baohui
    Liu, Yongyu
    Wu, Shi Xiu
    Kuang, Yukang
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma Haitao
    Xu, Shaofa
    Xu, Shidong
    Wang, Ping
    Mao, Weimin
    Pang, Zuoliang
    Hou, Shengcai
    Yang, Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC)
    He, Jie
    Zhang, Xiangru
    Li, Junling
    Han, Baohui
    Liu, Yongyu
    Wu, Shixiu
    Kuang, Y.
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma, Haitao
    Xu, Shidong
    Xu, Shaofa
    Wang, P.
    Mao, Weimin
    Pang, Z.
    Hou, S.
    Yang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1318 - S1319
  • [33] A phase I/II study of TPX-0131, a novel oral ALK tyrosine kinase inhibitor, in patients with ALK plus advanced/metastatic NSCLC
    Solomon, B. J.
    Millward, M.
    Kim, D-W.
    Park, E. K.
    Lin, J. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1034 - S1034
  • [34] A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.
    Jie, H.
    Xiangru, Z.
    Han, B.
    Liu, Y.
    Wang, Q.
    Xu, S.
    Sheng, Y.
    Li, Q.
    Wu, S.
    Chen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Primary results of ALESIA: A randomised, phase III, open-label study of alectinib vs crizotinib in Asian patients with treatment-naive ALK plus advanced NSCLC
    Zhou, C.
    Lu, Y.
    Kim, S-W.
    Reungwetwattana, T.
    Zhou, J.
    Zhang, Y.
    He, J.
    Yang, J. J.
    Cheng, Y.
    Lee, S. H.
    Bu, L.
    Xu, T.
    Yang, L.
    Wang, C.
    Morcos, P. N.
    Mitry, E.
    Liu, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 740 - 740
  • [36] Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study
    Lin, J. J.
    Muzikansky, A.
    Kennedy, E.
    Kuberski, H.
    Stober, L. L.
    Wanat, A. C.
    Azzoli, C. G.
    Lennes, I
    Sequist, L., V
    Dagogo-Jack, I
    Shaw, A. T.
    Gainor, J. F.
    ESMO OPEN, 2022, 7 (01)
  • [37] Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR plus NSCLC.
    Yue, Dongsheng
    Xu, Shi-Dong
    Wang, Qun
    Li, Xiaofei
    Shen, Yi
    Zhao, Heng
    Chen, Chun
    Mao, Weimin
    Liu, Wei
    Liu, Junfeng
    Zhang, Lan-Jun
    Ma, Haitao
    Li, Qiang
    Yang, Yue
    Liu, Yongyu
    Chen, Haiquan
    Zhang, Zhenfa
    Zhang, Bin
    Gong, Fuyu
    Wang, Changli
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] A phase I/II study with a CNS-penetrant, selective ALK inhibitor alectinib in ALK-rearranged non-small cell lung cancer (ALK plus NSCLC) patients (pts): Updates on progression free survival (PFS) and safety results from AF-001JP.
    Ohe, Yuichiro
    Nishio, Makoto
    Kiura, Katsuyuki
    Seto, Takashi
    Nakagawa, Kazuhiko
    Maemondo, Makoto
    Inoue, Akira
    Hida, Toyoaki
    Yoshioka, Hiroshige
    Harada, Masao
    Nogami, Naoyuki
    Murakami, Haruyasu
    Takeuchi, Kengo
    Shimada, Tadashi
    Kuriki, Hiroshi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Reckamp, Karen L.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather
    Carter, Corey A.
    Gockerman, Jon P.
    Lovly, Christine
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S36 - S37
  • [40] Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK plus non-small cell lung cancer (NSCLC)
    Lovly, Christine M.
    Infante, Jeffrey R.
    Blumenschein, George R.
    Reckamp, Karen
    Wakelee, Heather
    Carter, Corey A.
    VVagar, Saiama N.
    Neal, Joel
    Gockerman, Jon P.
    Dukart, Gary
    Harrow, Kimberly
    Liang, Chris
    Gibbons, James J.
    Horn, Leora
    CANCER RESEARCH, 2016, 76
12345